U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support ...
The PBM says the payment model more closely aligns with the costs pharmacies often face due to "manufacturer pricing actions." ...
The PBM is pivoting to a cost-based reimbursement model, which it says will reduce variation in how pharmacies are paid.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback